FindTrial
Sign In

Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03906357
Enrollment
Unknown
Registered
2019-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.

Interventions

DRUGPemigatinib

Sponsors

H. Lee Moffitt Cancer Center and Research Institute
CollaboratorOTHER
Incyte Corporation
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026